17:11 EDT Aardvark Therapeutics (AARD) files $400M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)
- Aardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch Next
- Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors
- Morning News Wrap-Up 3/2/26: Monday’s Biggest Stock Market Stories!
- Aardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald